Full Press Release Details
ASTELLAS LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES.
REGN
ASTELLAS LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES
Key Takeaway: ASTELLAS LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES